Induced Pluripotent Stem Cells (iPSCs)

Pluripotent stem cells generated by forced expression of defined transcription factors (“reprogramming factors”) in somatic cells. iPSCs can differentiate into cell types from all three germ layers and self-renew indefinitely in culture. Their central relevance to aging biology is twofold: (1) reprogramming erases the epigenetic age of donor cells, resetting DNA methylation clocks to an embryonic-like state regardless of donor age, and (2) directed differentiation of iPSCs from aged donors generates “young” cell types that serve as the substrate for ipsc-derived-cell-therapy and are mechanistically central to the partial-reprogramming hypothesis.

Schema adaptation note: The type: cell-type schema was designed for in-vivo cell populations. iPSCs are generated in vitro and have no tissue of origin or in-vivo niche. tissue-of-origin: is left empty and source-cell types are documented in body. typical-niche: describes culture conditions. key-aging-phenotypes: is empty because iPSCs themselves do not exhibit aging phenotypes. These adaptations are flagged per CLAUDE.md conventions.

Discovery and foundational papers

iPSCs were first generated from mouse embryonic and adult fibroblasts by Kazutoshi Takahashi and Shinya Yamanaka in 2006 by retroviral delivery of four transcription factors: Oct4, Sox2, Klf4, and c-Myc (the “OSKM” or “Yamanaka” factors) ¹. The resulting cells expressed embryonic stem cell (ESC) markers, formed teratomas in vivo, and contributed to chimeric mice. This was the first demonstration that a fully differentiated adult somatic cell could be converted to pluripotency without nuclear transfer.

Human iPSCs were reported simultaneously in late 2007 by two independent groups:

Takahashi et al. 2007 (Yamanaka lab) used the same OSKM factor set delivered by retrovirus to adult human dermal fibroblasts ². The resulting hiPSCs expressed pluripotency markers (OCT4, NANOG, SSEA-3/4, TRA-1-60, TRA-1-81), formed teratomas in nude mice, and resembled human ESCs by global gene expression.
Yu et al. 2007 (Thomson lab) used an alternative factor set — OCT4, SOX2, NANOG, and LIN28 — delivered by lentivirus ³. This demonstrated that c-MYC (a proto-oncogene) is dispensable for human reprogramming, with significant implications for safety.

Shinya Yamanaka shared the 2012 Nobel Prize in Physiology or Medicine with John Gurdon for this work. unsourced — Nobel citation does not require a primary reference, but the OSKM kinetics and efficiency claims below do.

Reprogramming factors and alternative combinations

The canonical OSKM set represents a minimal pluripotency-induction cocktail, not the only one. Key alternatives:

Factors	Source	Notes
OCT4, SOX2, KLF4, c-MYC	Yamanaka 2006/2007	Canonical; retrovirally delivered; c-MYC raises oncogenic risk
OCT4, SOX2, NANOG, LIN28	Thomson 2007	c-MYC-free; lentiviral; comparable efficiency to OSKM
OCT4, SOX2, KLF4 (no c-MYC)	Various	Reduced efficiency (substantially lower than OSKM; exact fold-change varies by system) unsourced; reduces transformation risk
Chemical cocktails (small molecules)	Hou 2013	Oct4-free (mouse); extended but possible without genetic manipulation
mRNA delivery (mRNA iPSC)	Warren 2010	Non-integrating; reduced mutagenic risk; lower efficiency historically

Delivery method safety hierarchy: mRNA/episomal/sendai-virus > lentiviral (integrating) > retroviral (silenced over time but present). Integration-free methods are now standard for clinical-grade iPSC derivation. unsourced — cite Warren 2010 mRNA iPSC if this claim is extracted for a study page.

Common somatic source cells

iPSCs can be generated from many somatic cell types. Efficiency and reprogramming kinetics vary by source:

Source cell	Relative efficiency	Practical notes
Dermal fibroblasts (skin biopsy)	Baseline (~0.01–0.1% with OSKM retroviruses)	Most characterized; requires invasive biopsy
Peripheral blood mononuclear cells (PBMCs)	Comparable	Minimally invasive (venipuncture); standard clinical source
Urine-derived epithelial cells	Lower	Non-invasive collection; useful in pediatrics
Keratinocytes	Higher than fibroblasts	Require skin biopsy
Dental pulp cells	High	Requires tooth extraction

For aging-research purposes, donor-age effects on reprogramming efficiency are modest: Lapasset et al. 2011 demonstrated that reprogramming efficiency from senescent (74S) and centenarian (92–101-year-old) fibroblasts using a six-factor OSKMNL cocktail was ~0.06%, similar to that from young proliferative fibroblasts (74P) under the same conditions, demonstrating that cellular senescence is not a barrier to iPSC generation ⁴. Standard four-factor OSKM was insufficient for senescent cells in that study; the addition of NANOG and LIN28 was required.

Pluripotency criteria

Three levels of evidence are used to assess iPSC pluripotency:

Marker expression — OCT4, SOX2, NANOG, SSEA-3/4, TRA-1-60, TRA-1-81, alkaline phosphatase (human); Oct4, Nanog, Sox2, SSEA-1, alkaline phosphatase (mouse). Required but not sufficient — immortalized lines can activate some markers without being truly pluripotent.
In-vitro trilineage differentiation — Formation of embryoid bodies (EBs) with spontaneous differentiation into ectoderm, mesoderm, and endoderm derivatives. Standard demonstration; now also assessed via directed differentiation protocols.
Teratoma assay (gold standard in-vivo) — Injection into immunodeficient mice (nude or SCID) produces benign tumors containing all three germ-layer derivatives (glandular epithelium, cartilage, neural rosettes). This confirms in-vivo pluripotency but is increasingly replaced by stringent in-vitro assays due to animal-use concerns.
Tetraploid complementation (mouse only; most stringent) — iPSC injection into tetraploid blastocysts generates an entirely iPSC-derived mouse. Not applicable to human cells; not used clinically.

Note: Mouse and human iPSCs differ in their pluripotency state: mouse iPSCs are typically “naive” (ground-state pluripotency; LIF-dependent), while human iPSCs are typically “primed” (epiblast-like; bFGF + Activin/Nodal-dependent). Naive human iPSCs can be generated but require special conditions. The bFGF vs LIF distinction underlies the different marker profiles (mouse SSEA-1 vs human SSEA-3/4).

Aging-biology relevance

Reprogramming erases epigenetic age

The most important property of iPSCs for aging biology is that the reprogramming process resets the DNA methylation clock to an embryonic-like state, regardless of the chronological age of the donor.

Lapasset et al. 2011 demonstrated this directly using a six-factor cocktail (OCT4, SOX2, KLF4, c-MYC, NANOG, LIN28 — designated OSKMNL): fibroblasts from very elderly donors (92-, 94-, 96-, and 101-year-old individuals) and from replicatively senescent 74-year-old donors were reprogrammed to iPSCs with a mean re-programming efficiency of 0.06% — similar to that achieved from young proliferative fibroblasts ⁴. The resulting iPSCs expressed endogenous pluripotency genes (OCT4, SOX2, NANOG, REX1), showed demethylation of OCT4 and NANOG promoters, re-expressed surface markers SSEA-4 and TRA-1-60, and clustered with hESCs rather than with parental fibroblasts by global transcriptome analysis. Telomere length was also reset: mean telomere size was increased relative to parental fibroblasts, comparable to H9 hESCs. The centenarian- and senescent-donor-derived iPSCs retained normal pluripotency and directed-differentiation capacity into all three germ layers. Note: Werner syndrome donors were NOT included in Lapasset 2011; this paper focuses exclusively on replicative senescence and very advanced chronological age.

Dimension	Status
Pathway conserved in humans?	yes
Phenotype conserved in humans?	yes
Replicated in humans?	yes — multiple labs

Olova et al. 2019 dissected the kinetics of methylation-age erasure during reprogramming: by applying Horvath’s multitissue age predictor to a published 49-day OSKM transduction time-course in human dermal fibroblasts (HDFs), they showed that epigenetic age (eAge) begins declining between days 3 and 7 post-transduction and proceeds steadily at a rate of 3.8 years/day (SE 0.27, p = 3.8 × 10⁻⁷) until day 20, well before cells reach full pluripotency (day ~28) ⁵. Critically, this eAge decline follows different kinetics from the loss of somatic gene expression, showing that the two processes can be uncoupled — eAge declines linearly while somatic marker gene expression in one fibroblast cluster (FSP1, COL3A1, TGFB2/3) remains stable until day 15 before rapidly declining. This “safe window” observation is mechanistically foundational to partial-reprogramming therapy: it suggests cells can be rejuvenated epigenetically without full dedifferentiation to a cancer-permissive pluripotent state. Note: this was an observational time-course study of continuous OSKM expression, NOT a controlled induction-then-withdrawal (“partial reprogramming by factor withdrawal”) experiment.

Implications for the information theory of aging

The finding that somatic cell epigenetic age is erasable and re-programmable in the same cell type supports information-theory-of-aging (the view that aging reflects accumulated loss of epigenetic information and that restoring this information can reverse functional aging). iPSC reprogramming provides the existence proof: the information to be young still exists in the genome of an aged cell — it just needs to be re-read. needs-replication — the mechanistic link between epigenetic age reset and functional rejuvenation at the organismal level is not established in humans; see partial-reprogramming for the in-vivo evidence.

Epigenetic memory of source tissue

iPSCs retain partial “epigenetic memory” of their source tissue — residual DNA methylation patterns from the parental cell type ⁶. This can bias directed differentiation: iPSCs derived from blood cells differentiate more efficiently into hematopoietic progenitors; those from cardiac fibroblasts retain cardiac methylation marks. Epigenetic memory fades over serial passaging. For aging-research applications, the choice of source cell type and passage number must be controlled. needs-replication — quantitative magnitude of memory bias vs. passage number varies across studies and reprogramming methods.

Distinction from embryonic stem cells (ESCs)

iPSCs and ESCs share pluripotency markers and trilineage differentiation capacity but differ in:

Somatic mutations — iPSCs accumulate the mutational burden of the donor cell through decades of somatic exposure (UV, replication errors, CHIP variants). ESCs derive from blastocysts with near-zero somatic mutation load.
Reprogramming-induced abnormalities — retroviral/lentiviral OSKM delivery causes insertional mutagenesis; even integration-free methods cause transcriptional stress and copy-number variations.
Epigenetic memory — iPSCs retain partial tissue-of-origin methylation; ESCs do not.
Immune compatibility — autologous iPSCs (patient-derived) should be immune-matched, but reprogramming + passaging can generate neoantigens from mutations or HLA changes. needs-replication — clinical immune-rejection rates in autologous iPSC-derived cell therapy are not yet characterized.

Therapeutic application

iPSCs are the cellular substrate for ipsc-derived-cell-therapy (see sibling page). Core clinical value: patient-specific pluripotent cells that can be differentiated into any replacement cell type (dopaminergic neurons, cardiomyocytes, beta cells, retinal pigment epithelium) without immune rejection and without the ethical constraints of ESC use.

Key aging-relevant differentiated cell types under clinical investigation: retinal pigment epithelium (RPE) for macular degeneration (most advanced; Phase I/II trials in Japan); dopaminergic neurons for Parkinson’s disease; T cells and NK cells for cancer immunotherapy; cardiomyocytes for heart failure.

See ipsc-derived-cell-therapy for clinical trial status, safety profile, and translation gaps. See in-vivo-partial-reprogramming-therapy for the in-vivo application of reprogramming factors in intact organisms.

Hallmark connections

Hallmark	Mechanism
epigenetic-alterations	iPSC reprogramming erases methylation age; the erasability implies aging = reversible epigenetic drift

iPSCs are not themselves carriers of aging hallmarks — they represent a rejuvenated cellular state. Their relevance to other hallmarks (cellular-senescence, stem-cell-exhaustion, genomic-instability) is indirect: aged donor cells that are inputs to reprogramming carry these hallmarks; the resulting iPSCs shed most of them (senescence is bypassed; epigenome reset; telomeres re-elongated), but accumulate new risks (somatic mutations, reprogramming-induced abnormalities).

Limitations and gaps

#gap/needs-human-replication — In-vivo rejuvenation via partial OSKM reprogramming is established in mouse models but not yet demonstrated in humans; iPSC-mediated functional rejuvenation at the organismal level remains hypothetical.
#gap/needs-replication — The extent to which epigenetic memory of source tissue affects aging-biology experiments in iPSC-derived cells is not systematically quantified.
#gap/no-mechanism — The molecular machinery by which OSKM factors reset the Horvath clock is not fully characterized; it likely involves TET-mediated active demethylation but causal chain is incomplete.
#gap/long-term-unknown — Long-term genomic stability of iPSC-derived cell grafts in human recipients is not established; somatic-mutation accumulation during reprogramming + expansion is a recognized but incompletely characterized risk.
#gap/needs-canonical-id — No specific Cell Ontology ID for induced pluripotent stem cells exists beyond the broader CL:0002248 (pluripotent stem cell). Wiki uses CL:0002248 with a notation. If a more specific CL ID is introduced, update frontmatter.

Footnotes

takahashi-yamanaka-2006-mouse-ipsc · n=multiple clones from adult tail-tip + embryonic fibroblasts · in-vitro · model: Mus musculus fibroblasts · local PDF available · doi:10.1016/j.cell.2006.07.024 ↩
takahashi-2007-human-ipsc · n=multiple clones from adult human dermal fibroblasts · in-vitro · model: Homo sapiens fibroblasts · PDF not locally available (closed-access) · doi:10.1016/j.cell.2007.11.019 · no-fulltext-access ↩
yu-2007-thomson-human-ipsc · n=multiple clones from human foreskin fibroblasts + IMR90 cells · in-vitro · model: Homo sapiens fibroblasts · PDF not locally available (closed-access) · doi:10.1126/science.1151526 · no-fulltext-access ↩
lapasset-2011-centenarian-ipsc-epigenetic-reset · n=cell lines from senescent (74S) and centenarian (92-, 94-, 96-, 101-yr-old) donors plus proliferative controls; 6-factor cocktail OSKMNL (OCT4, SOX2, KLF4, c-MYC, NANOG, LIN28); reprogramming efficiency 0.06% · in-vitro · model: Homo sapiens fibroblasts · local PDF available · doi:10.1101/gad.173922.111 · Note: Werner syndrome donors NOT included in this paper ↩ ↩²
olova-2019-partial-reprogramming-epigenetic-age · n=multiple time-point samples (days 0, 3, 7, 11, 15, 20, 28, 35, 42, 49) from continuous 49-day OSKM transduction time-course in human dermal fibroblasts (HDFs); eAge decline rate 3.8 yr/day (SE 0.27, p=3.8×10⁻⁷) from days 3–20 · in-vitro · model: Homo sapiens fibroblasts → iPSC · local PDF available · doi:10.1111/acel.12877 ↩
hochedlinger-jaenisch-2015-ipsc-epigenetic-reprogramming-review · review · model: mouse + human · local PDF available (downloaded on demand) · doi:10.1101/cshperspect.a019448 ↩

🧬 Aging Wiki

Explorer

induced-pluripotent-stem-cells